JP2020533022A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533022A5
JP2020533022A5 JP2020535276A JP2020535276A JP2020533022A5 JP 2020533022 A5 JP2020533022 A5 JP 2020533022A5 JP 2020535276 A JP2020535276 A JP 2020535276A JP 2020535276 A JP2020535276 A JP 2020535276A JP 2020533022 A5 JP2020533022 A5 JP 2020533022A5
Authority
JP
Japan
Prior art keywords
seq
par4
binding protein
sequence
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020535276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533022A (ja
JP7733443B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/050985 external-priority patent/WO2019046912A1/en
Publication of JP2020533022A publication Critical patent/JP2020533022A/ja
Publication of JP2020533022A5 publication Critical patent/JP2020533022A5/ja
Priority to JP2023087663A priority Critical patent/JP2023116543A/ja
Application granted granted Critical
Publication of JP7733443B2 publication Critical patent/JP7733443B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020535276A 2017-09-11 2018-09-11 ヒトトロンビン受容体par4に対する結合タンパク質 Active JP7733443B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023087663A JP2023116543A (ja) 2017-09-11 2023-05-29 ヒトトロンビン受容体par4に対する結合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017903685A AU2017903685A0 (en) 2017-09-11 Antagonists of the human thrombin receptor, PAR4
AU2017903685 2017-09-11
PCT/AU2018/050985 WO2019046912A1 (en) 2017-09-11 2018-09-11 HUMAN THROMBIN RECEPTOR BINDING PROTEINS, PAR4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023087663A Division JP2023116543A (ja) 2017-09-11 2023-05-29 ヒトトロンビン受容体par4に対する結合タンパク質

Publications (3)

Publication Number Publication Date
JP2020533022A JP2020533022A (ja) 2020-11-19
JP2020533022A5 true JP2020533022A5 (enExample) 2021-10-21
JP7733443B2 JP7733443B2 (ja) 2025-09-03

Family

ID=65633328

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535276A Active JP7733443B2 (ja) 2017-09-11 2018-09-11 ヒトトロンビン受容体par4に対する結合タンパク質
JP2023087663A Pending JP2023116543A (ja) 2017-09-11 2023-05-29 ヒトトロンビン受容体par4に対する結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023087663A Pending JP2023116543A (ja) 2017-09-11 2023-05-29 ヒトトロンビン受容体par4に対する結合タンパク質

Country Status (17)

Country Link
US (2) US11780915B2 (enExample)
EP (2) EP3681911B1 (enExample)
JP (2) JP7733443B2 (enExample)
KR (1) KR102755742B1 (enExample)
CN (1) CN111670198B (enExample)
AU (1) AU2018328764B2 (enExample)
CA (1) CA3075523A1 (enExample)
DK (1) DK3681911T3 (enExample)
ES (1) ES2999094T3 (enExample)
FI (1) FI3681911T3 (enExample)
HR (1) HRP20241684T1 (enExample)
HU (1) HUE069649T2 (enExample)
IL (1) IL273202B2 (enExample)
LT (1) LT3681911T (enExample)
PT (1) PT3681911T (enExample)
SI (1) SI3681911T1 (enExample)
WO (1) WO2019046912A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681911B1 (en) * 2017-09-11 2024-11-27 Monash University Binding proteins to the human thrombin receptor, par4
CN112852958A (zh) * 2021-04-04 2021-05-28 吉林大学 一种检测替格瑞洛抗血小板效果的试剂盒
CN115558015B (zh) * 2022-10-12 2024-01-19 生工生物工程(上海)股份有限公司 一种从gst融合蛋白酶切后的产物中纯化无gst标签的目的蛋白的方法和产品

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676A (en) 1846-07-31 roller
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2672899A (en) * 1998-02-27 1999-09-15 Regents Of The University Of California, The Protease-activated receptor 4 and uses thereof
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6111075A (en) * 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
US6489447B1 (en) 1998-05-06 2002-12-03 Genentech, Inc. Protein purification
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
JP2003526625A (ja) * 1999-07-23 2003-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 血小板の活性化の調節
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
EP1333032A4 (en) 2000-10-06 2005-03-16 Kyowa Hakko Kogyo Kk PROCESS FOR PURIFYING ANTIBODY
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
WO2005003156A1 (en) 2003-07-04 2005-01-13 Affibody Ab Polypeptides having binding affinity for her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010080538A1 (en) 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US20060263367A1 (en) 2005-05-23 2006-11-23 Fey Georg H Bispecific antibody devoid of Fc region and method of treatment using same
US7879792B2 (en) 2005-06-02 2011-02-01 The Regents Of The University Of Michigan Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
EP1945668A4 (en) 2005-08-15 2009-07-22 Arana Therapeutics Ltd SYNTHETIC ANTIBODIES WITH FRAMEWORK REGIONS OF NEUWELTPRIMATEN
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
BR112014026493A2 (pt) 2012-04-26 2017-06-27 Bristol Myers Squibb Co derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta
EP3681911B1 (en) 2017-09-11 2024-11-27 Monash University Binding proteins to the human thrombin receptor, par4

Similar Documents

Publication Publication Date Title
JP7551693B2 (ja) NKp46結合タンパク質の可変領域
JP2024150751A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2020516240A5 (enExample)
IL295295A (en) Antibodies against fcrl5 and methods of their use
JP2023116543A5 (enExample)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2019205480A5 (enExample)
JP2020533022A5 (enExample)
CN111712521A (zh) Cd38蛋白抗体及其应用
JPWO2019204564A5 (enExample)
JP2025511288A (ja) 抗pvrig抗体、その医薬組成物及びその使用
FI3681911T3 (fi) Ihmisen trombiinireseptori PAR4:ään sitoutuvia proteiineja
JPWO2021007260A5 (enExample)
JPWO2021170068A5 (enExample)
JPWO2021224913A5 (enExample)
JPWO2023028653A5 (enExample)
JPWO2021042019A5 (enExample)
JPWO2022173670A5 (enExample)
JPWO2020076789A5 (enExample)
JPWO2021068841A5 (enExample)
JPWO2021119531A5 (enExample)
JPWO2023034922A5 (enExample)
JPWO2021130502A5 (enExample)
WO2023143565A1 (en) Anti-btla antibodies and uses thereof in treating cancer